SacredBod's longer take on Type 1 Collagen — context the structured blocks above don't capture.
Type 1 collagen is the structural scaffolding of the human body — the protein that gives skin its resilience, tendons their tensile strength, and bones their flexibility. It constitutes roughly 90% of the collagen in skin and the majority of the matrix in tendons, ligaments, and bone. In supplement form, it is typically sold as “hydrolyzed collagen” or “collagen peptides” — enzymatically cleaved fragments with molecular weights of 1–3 kDa that are small enough to be absorbed through the intestinal wall and distributed to target tissues.
The clinical evidence for collagen has grown substantially in recent years, particularly for joint and skin applications. A 2024 randomized trial in Frontiers in Nutrition evaluated 10 g/day of collagen peptides in adults with grade II–III knee osteoarthritis over six months. The treatment group showed significant reductions in VAS pain scores, Lequesne algofunctional index, C-reactive protein, and erythrocyte sedimentation rate compared to placebo. No adverse effects were reported, and the supplement was well tolerated. This aligns with earlier work: a 2013 trial in Current Medical Research and Opinion found that 5 g/day of collagen peptides significantly reduced activity-related knee joint discomfort in athletes over 12 weeks.
The skin evidence is equally robust. Multiple randomized trials have demonstrated improvements in skin elasticity, hydration, and wrinkle depth with collagen peptide supplementation, typically at 2.5–10 g/day. The mechanism appears to involve both direct provision of collagen-building amino acids (glycine, proline, hydroxyproline) and stimulation of fibroblast activity through bioactive peptides.
A critical practical point that supplement marketing often obscures: the effective doses used in positive trials are far higher than what most capsule products provide. A typical collagen capsule contains 500–1,000 mg. To reach the 10 g/day dose used in the 2024 knee OA trial, you would need 10–20 capsules daily. Powder form — mixed into coffee, smoothies, or water — is the only practical way to achieve therapeutic dosing. This is not a minor detail: consumers buying collagen capsules and expecting joint pain relief are likely underdosing by an order of magnitude.
Quality also matters. Marine (fish) collagen has smaller peptides and may be more bioavailable than bovine sources, though both have demonstrated efficacy. The peptide size (1–3 kDa) and the presence of specific bioactive sequences — particularly proline-hydroxyproline dipeptides — are thought to drive the tissue-specific effects. Third-party testing for heavy metals is important, especially for marine sources.
For consumers interested in connective tissue support, type 1 collagen is a promising option with a favorable safety profile and growing clinical evidence. The key is using the right form (powder), the right dose (5–10 g/day), and the right expectations (gradual improvement over 2–6 months, not overnight relief).